Biotechnology company
Appears in 1 story · Last updated Nov 8, 2026
Acquired by Johnson & Johnson in 2025
Johnson & Johnson's experimental prostate cancer drug JNJ-6143 shrank tumors in 12 of 16 patients with measurable disease in a Phase 1 trial. The results were presented October 24 at the European Society for Medical Oncology Congress, and J&J's press release followed a day later.
Updated 3 days ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
